Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock Has Average Price Target of $13.08

Posted by Stanley Muller on Nov 1st, 2026

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Free Report) have been assigned an average recommendation of “Hold” from the nine analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $13.50.

VNDA has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Monday, October 5th. Wall Street Zen upgraded Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday. Zacks Research downgraded Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, October 15th. Finally, B. Riley Financial reiterated a “buy” rating and set a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th.

Get Our Latest Analysis on VNDA

Institutional Investors Weigh In On Vanda Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Quantbot Technologies LP purchased a new position in Vanda Pharmaceuticals in the 2nd quarter worth $29,000. Legal & General Group Plc bought a new stake in Vanda Pharmaceuticals in the second quarter worth $34,000. Allworth Financial LP bought a new stake in Vanda Pharmaceuticals in the second quarter worth $43,000. Walleye Capital LLC purchased a new stake in Vanda Pharmaceuticals during the second quarter valued at about $76,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Vanda Pharmaceuticals during the second quarter valued at about $93,000. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Stock Down 6.4%

Vanda Pharmaceuticals stock opened at $3.79 on Tuesday. Vanda Pharmaceuticals has a 1-year low of $3.74 and a 1-year high of $9.94. The firm has a market capitalization of $229.14 million, a price-to-earnings ratio of -0.82 and a beta of 0.69. The company has a current ratio of 1.54, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $4.79 and a 200 day simple moving average of $6.22.

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.31. Vanda Pharmaceuticals had a negative return on equity of 62.70% and a negative net margin of 119.87%. The firm had revenue of $69.81 million during the quarter, compared to analyst estimates of $69.20 million. On average, analysts predict that Vanda Pharmaceuticals will post -2.68 earnings per share for the current year.

Vanda Pharmaceuticals Company Profile

(Get Free Report)

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.